Lennox-Gastaut syndrome Market to Expand Significantly by 2034, States DelveInsight Report
DelveInsight's 'Lennox–Gastaut syndrome Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Lennox–Gastaut syndrome, historical and forecasted epidemiology as well as the Lennox–Gastaut syndrome market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
The Lennox–Gastaut syndrome market report covers emerging drugs, current treatment practices, market share of the individual therapies, and current & forecasted market size from 2020 to 2034. It also evaluates the current treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
To Know in detail about the Lennox–Gastaut syndrome market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Lennox–Gastaut syndrome Market Forecast
Some of the key facts of the Lennox–Gastaut syndrome Market Report:
The Lennox–Gastaut syndrome market size was valued ~596 million in 2022 and is anticipated to grow with a significant CAGR during the study period (2020-2034)
In June 2024, UCB, a global biopharmaceutical company, announced that Epilepsia published results from a comprehensive scoping review evaluating the effectiveness of FINTEPLA® (fenfluramine) in reducing the frequency of generalized tonic-clonic seizures (GTCS) and tonic-clonic seizures (TCS) in patients with developmental and epileptic encephalopathies (DEEs). The review demonstrated a significant reduction in both GTCS and TCS across various DEEs, further supporting the data from the FINTEPLA clinical trial program. FINTEPLA is approved by the U.S. Food and Drug Administration (FDA) for treating seizures associated with Dravet syndrome and Lennox-Gastaut syndrome in patients aged two years and older.
In June 2024, Takeda (TSE:4502/NYSE:TAK) has announced topline results from its SKYLINE and SKYWAY studies. SKYLINE (TAK-935-3001) was a multicenter, randomized, double-blind Phase 3 trial that assessed soticlestat (TAK-935) in combination with standard care versus placebo plus standard care in patients with refractory Dravet syndrome (DS). While soticlestat did not meet the primary endpoint of reducing convulsive seizure frequency compared to placebo (p-value = 0.06), it showed clinically meaningful and nominally significant results in six key secondary endpoints, including responder rates, caregiver and clinician global impressions of improvement, and seizure intensity and duration scales during the 16-week treatment period (all p-values ≤ 0.008).
DelveInsight's analysis forecasts that the Lennox-Gastaut Syndrome market will expand at a CAGR of 4.5% from 2024 to 2034.
According to DelveInsight's epidemiology model, there were approximately 115,000 prevalent cases of Lennox-Gastaut Syndrome in the 7MM in 2023. This figure is expected to increase over the forecast period (2024-2034), largely due to heightened awareness and advancements in diagnostic methods.
In 2023, the diagnosed prevalent cases of Lennox-Gastaut Syndrome across the 7MM totaled approximately 81,000. This number is expected to increase throughout the forecast period.
In 2023, the United States recorded the highest number of diagnosed prevalent cases of Lennox-Gastaut Syndrome, with around 34,000 cases, a figure projected to rise throughout the forecast period.
In 2023, the diagnosed prevalent cases of Lennox-Gastaut Syndrome in the US were distributed by gender, with males representing about 25,000 cases and females accounting for approximately 9,000 cases.
In 2023, among the EU4 and the UK, Germany recorded the highest number of diagnosed prevalent cases of Lennox-Gastaut Syndrome, with roughly 11,000 cases. France followed with approximately 9,600 cases, and Italy had around 8,800 cases.
In 2023, Japan had the fewest diagnosed prevalent cases of Lennox-Gastaut Syndrome, with around 3,000 cases.
Key Lennox–Gastaut syndrome Companies: Takeda /Ovid, SK Life Science, Inc., Epygenix, CuroNZ Ltd, Eisai, and others
Key Lennox–Gastaut syndrome Therapies: Soticlestat, Carisbamate, EPX-100, NRP2945, Fycompa, TAK-935/OV935 (Soticlestat), and others
The Lennox–Gastaut syndrome epidemiology based on gender analyzed that Lennox–Gastaut syndrome is found to be more prevalent in males than in females, for some undefined reason, with the male to female ratio being 1:6 (relative risk, 5.31).
Lennox–Gastaut syndrome Overview
Lennox-Gastaut syndrome (LGS) is a rare and severe form of epilepsy that typically begins in early childhood, often between ages 3 and 5. It is characterized by multiple types of seizures, including tonic (stiffening) and atonic (loss of muscle tone) seizures. People with LGS also experience developmental delays, cognitive impairments, and behavioral issues. The causes of LGS can vary, including genetic factors, brain injury, or other underlying conditions. Treatment usually involves a combination of medications, and in some cases, surgery or dietary therapies, to manage the seizures and improve quality of life.
Get a Free sample for the Lennox–Gastaut syndrome Market Report -
Lennox–Gastaut syndrome Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.
Lennox–Gastaut syndrome Epidemiology Segmentation:
The Lennox–Gastaut syndrome market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:
Total Prevalent Cases of Lennox–Gastaut syndrome in the 7MM
Total Diagnosed Prevalent Cases of Lennox–Gastaut syndrome in the 7MM
Gender-specific Diagnosed Prevalent Cases of Lennox–Gastaut syndrome in the 7MM
Seizures-specific Diagnosed Prevalent Cases of Lennox Gastaut syndrome in the 7MM
Download the report to understand which factors are driving Lennox–Gastaut syndrome epidemiology trends @ Lennox–Gastaut syndrome Epidemiological Insights
Lennox–Gastaut syndrome Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Lennox–Gastaut syndrome market or expected to get launched during the study period. The analysis covers Lennox–Gastaut syndrome market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Lennox–Gastaut syndrome Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Lennox–Gastaut syndrome Therapies and Key Companies
To know more about Lennox–Gastaut syndrome treatment, visit @ Lennox–Gastaut syndrome Medications
Lennox–Gastaut syndrome Market Strengths
The use of off-label branded and generic prescription medications targeted at individual symptoms of LennoxGastaut syndrome (LGS)
Lennox–Gastaut syndrome Market Opportunities
New therapeutic options are needed to address the unmet need for effective and curative therapies for Lennox-Gastaut syndrome (LGS).
Scope of the Lennox–Gastaut syndrome Market Report
Study Period: 2020–2034
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
Key Lennox–Gastaut syndrome Companies: Takeda /Ovid, SK Life Science, Inc., Epygenix, CuroNZ Ltd, Eisai, Takeda, Ovid, and others
Key Lennox–Gastaut syndrome Therapies: Soticlestat, Carisbamate, EPX-100, NRP2945, Fycompa, TAK-935/OV935 (Soticlestat), and others
Lennox–Gastaut syndrome Therapeutic Assessment: Lennox–Gastaut syndrome current marketed and Lennox–Gastaut syndrome emerging therapies
Lennox–Gastaut syndrome Market Dynamics: Lennox–Gastaut syndrome market drivers and Lennox–Gastaut syndrome market barriers
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
Lennox–Gastaut syndrome Unmet Needs, KOL's views, Analyst's views, Lennox–Gastaut syndrome Market Access and Reimbursement
Table of Contents
1. Lennox–Gastaut syndrome Market Report Introduction
2. Executive Summary for Lennox–Gastaut syndrome
3. SWOT analysis of Lennox–Gastaut syndrome
4. Lennox–Gastaut syndrome Patient Share (%) Overview at a Glance
5. Lennox–Gastaut syndrome Market Overview at a Glance
6. Lennox–Gastaut syndrome Disease Background and Overview
7. Lennox–Gastaut syndrome Epidemiology and Patient Population
8. Country-Specific Patient Population of Lennox–Gastaut syndrome
9. Lennox–Gastaut syndrome Current Treatment and Medical Practices
10. Lennox–Gastaut syndrome Unmet Needs
11. Lennox–Gastaut syndrome Emerging Therapies
12. Lennox–Gastaut syndrome Market Outlook
13. Country-Wise Lennox–Gastaut syndrome Market Analysis (2020–2034)
14. Lennox–Gastaut syndrome Market Access and Reimbursement of Therapies
15. Lennox–Gastaut syndrome Market Drivers
16. Lennox–Gastaut syndrome Market Barriers
17. Lennox–Gastaut syndrome Appendix
18. Lennox–Gastaut syndrome Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight
About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.
Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
2 hours ago
- Globe and Mail
Diabetic Retinopathy Pipeline Outlook 2025: Clinical Trial Studies, EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and Companies
DelveInsight's, ' Diabetic Retinopathy Pipeline Insights 2025 ' report provides comprehensive insights about 50+ companies and 55+ pipeline drugs in the Diabetic Retinopathy pipeline landscape. It covers the Diabetic Retinopathy pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Diabetic Retinopathy pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Explore the comprehensive insights by DelveInsight and stay ahead in understanding the Diabetic Retinopathy Treatment Landscape. Click here to read more @ Diabetic Retinopathy Pipeline Outlook Key Takeaways from the Diabetic Retinopathy Pipeline Report On August 18, 2025 (Monday), findings published online in JAMA Ophthalmology (August 14 edition) revealed that semaglutide therapy in adults with diabetes does not raise the risk of developing eye disorders or diabetic retinopathy. On August 15, 2025, Eyepoint Pharmaceuticals Inc. carried out a randomized, double-masked clinical trial assessing the ocular safety and efficacy of two different doses of the EYP-1901 IVT insert, compared with a sham treatment. On August 18, 2025, Genentech Inc. initiated a clinical trial designed to investigate both ocular and systemic safety, tolerability, and efficacy of RO7446603 in patients with diabetic macular edema (DME). The study includes two main parts: Phase I (Parts 1–4), which examined the safety of single and multiple intravitreal (IVT) doses as monotherapy or in combination with IVT aflibercept or IVT faricimab (administered separately), and Phase II (Part 5) for further evaluation. DelveInsight's Diabetic Retinopathy pipeline report depicts a robust space with 50+ active players working to develop 55+ pipeline therapies for Diabetic Retinopathy treatment. The leading Diabetic Retinopathy Companies such as Kodiak Sciences, Novartis, Regenxbio Inc., OcuTerra Therapeutics, Ocular Therapeutix, Bayer, RemeGen, Roche, Ocuphire Pharma, Adverum Biotechnologies, Boehringer Ingelheim, and others. Promising Diabetic Retinopathy Pipeline Therapies such as Runcaciguat (BAY1101042), OTT166, COLIRIOBCN070660, Brimonidine, and others. Discover groundbreaking developments in Diabetic Retinopathy therapies! Gain in-depth knowledge of key Diabetic Retinopathy clinical trials, emerging drugs, and market opportunities @ Diabetic Retinopathy Clinical Trials Assessment Diabetic Retinopathy Emerging Drugs Profile Tarcocimab tedromer: Kodiak Sciences Tarcocimab is an investigational anti-VEGF therapy built on Kodiak's proprietary Antibody Biopolymer Conjugate (""ABC"") Platform and is designed to maintain potent and effective drug levels in ocular tissues for longer than existing available agents. Kodiak's objective with tarcocimab is to enable earlier treatment and prevention of vision loss for patients with diabetic retinopathy and to develop a new durability agent to improve outcomes for patients with retinal vascular diseases. Currently, the drug is in Phase III stage of its clinical trial for the treatment of diabetic retinopathy. OTT166: Ocuterra Therapeutics Nesvategrast (OTT166) is an investigational, novel, patented, potent and selective small molecule RGD integrin inhibitor designed with purpose engineering to have an optimum balance of physiochemical properties to allow it to distribute to the retina in high concentrations after topical (eye drop) administration to the eye. In preclinical studies, nesvategrast selectively inhibited key RGD integrin subtypes, including αvβ3, to regulate cellular responses to VEGF and other growth factors known to contribute to development and progression of diabetic retinopathy and other ocular diseases. In early clinical trials in patients with diabetic retinal disease, nesvategrast eye drops have demonstrated preliminary evidence of tolerability and biological activity. Currently, the drug is in Phase II stage of its clinical trial for the treatment of Diabetic retinopathy. APX3330: Apexian Pharmaceuticals APX3330 is a first-in-class, small molecule, oral inhibitor of the transcription factor regulator Ref-1 (reduction-oxidation effector factor-1). With a novel dual mechanism of action, APX3330 blocks the downstream pathways those involving angiogenesis (VEGF) and inflammation (NFkB) to decrease abnormal activation of both angiogenesis, and of inflammatory pathways that are implicated across several ocular diseases, including DR, DME, and age-related macular degeneration (AMD). APX3330 has shown a favorable safety and tolerability profile in 12 clinical trials conducted in healthy, hepatitis, cancer, and diabetic subjects. Currently, the drug is in Phase II stage of its clinical trial for the treatment of diabetic retinopathy. OTX-TKI: Ocular Therapeutix OTX-TKI is an investigational bioresorbable, hydrogel implant incorporating axitinib, a small molecule, multi-target, tyrosine kinase inhibitor with anti-angiogenic properties, being evaluated for the treatment of wet age-related macular degeneration (wet AMD) and other retinal diseases. Currently, the drug is in Phase I stage of its clinical trial for the treatment of Diabetic retinopathy. The Diabetic Retinopathy Pipeline report provides insights into The report provides detailed insights about companies that are developing therapies for the treatment of Diabetic Retinopathy with aggregate therapies developed by each company for the same. It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Diabetic Retinopathy Treatment. Diabetic Retinopathy Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects. Diabetic Retinopathy Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Diabetic Retinopathy market Stay informed about the Diabetic Retinopathy pipeline trends! Uncover critical updates on therapeutic innovations and their potential impact on patients and the healthcare industry @ Diabetic Retinopathy Unmet Needs Diabetic Retinopathy Companies Kodiak Sciences, Novartis, Regenxbio Inc., OcuTerra Therapeutics, Ocular Therapeutix, Bayer, RemeGen, Roche, Ocuphire Pharma, Adverum Biotechnologies, Boehringer Ingelheim, and others. Diabetic Retinopathy pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as Oral Intravenous Subcutaneous Parenteral Topical Diabetic Retinopathy Pipeline Products have been categorized under various Molecule types such as Recombinant fusion proteins Small molecule Monoclonal antibody Peptide Polymer Gene therapy Transform your understanding of the Diabetic Retinopathy Pipeline! See the latest progress in drug development and clinical research @ Diabetic Retinopathy Market Drivers and Barriers, and Future Perspectives Scope of the Diabetic Retinopathy Pipeline Report Coverage- Global Diabetic Retinopathy Companies- Kodiak Sciences, Novartis, Regenxbio Inc., OcuTerra Therapeutics, Ocular Therapeutix, Bayer, RemeGen, Roche, Ocuphire Pharma, Adverum Biotechnologies, Boehringer Ingelheim, and others. Diabetic Retinopathy Pipeline Therapies- Runcaciguat (BAY1101042), OTT166, COLIRIOBCN070660, Brimonidine, and others. Diabetic Retinopathy Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination Diabetic Retinopathy Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III Dive deep into rich insights for new drugs for Diabetic Retinopathy Treatment, Visit @ Diabetic Retinopathy Market Drivers and Barriers, and Future Perspective Table of Content Introduction Executive Summary Diabetic Retinopathy: Overview Pipeline Therapeutics Therapeutic Assessment Diabetic Retinopathy– DelveInsight's Analytical Perspective Late Stage Products (Phase III) KSI-301: Kodiak Sciences Drug profiles in the detailed report….. Mid Stage Products (Phase II) RGX 314: Regenxbio Inc Drug profiles in the detailed report….. Early Stage Products (Phase I) OTX-TKI: Ocular Therapeutix Drug profiles in the detailed report….. Preclinical and Discovery Stage Products Drug name: Company name Drug profiles in the detailed report….. Inactive Products Diabetic Retinopathy Key Companies Diabetic Retinopathy Key Products Diabetic Retinopathy- Unmet Needs Diabetic Retinopathy- Market Drivers and Barriers Diabetic Retinopathy- Future Perspectives and Conclusion Diabetic Retinopathy Analyst Views Diabetic Retinopathy Key Companies Appendix About Us DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Globe and Mail
2 hours ago
- Globe and Mail
Gene Therapy Competitive Landscape Report 2025
DelveInsight's, ' Gene Therapy Competitive landscape, 2025,' report provides comprehensive insights about 180+ companies and 200+ drugs in Gene Therapy Competitive landscape. It covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Explore the comprehensive insights by DelveInsight and stay ahead in understanding the Gene Therapy Treatment Landscape @ Gene Therapy Pipeline Outlook Key Takeaways from the Gene Therapy Competitive Landscape Report On 17 August 2025, MeiraGTx LLC conducted a study of individual participation in this study will be approximately 54 months for participants who received AAV-GAD in Study MGT-GAD-025 and approximately 60 months for participants who received sham surgery in Study MGT-GAD-025. On 15 August 2025, Janssen Research & Development LLC organized a Phase 3 Follow-up Study of for the Treatment of X-linked Retinitis Pigmentosa Associated With Variants in the RPGR Gene. On 13 August 2025, REGENXBIO Inc. announced a phase I/II/III study to evaluate the safety, tolerability, pharmacodynamics (microdystrophin protein levels), pharmacokinetic, and clinical efficacy of RGX-202 when administered IV as one-time dose to ambulant male participants with Duchenne. A comprehensive, short-term, prophylactic immunosuppression regimen will be administered during treatment to mitigate a potential immune response. This study is being conducted in three sequential parts: a phase I/II study (Part 1), a phase 3 pivotal study (Part 2) and a confirmatory study (Part 3). Part 1 will study a one-time dose of RGX-202 (1x10^14 or 2x10^14 GC/kg) in up to 15 participants with Duchenne. DelveInsight's Gene Therapy Competitive landscape report depicts a robust space with 180-+ active players working to develop 200+ pipeline therapies for Gene Therapy treatment. The leading Gene Therapy Companies such as Pfizer, Ultragenyx Pharmaceutical Inc, Rocket Pharmaceuticals, Adverum Biotechnologies, Kyverna Therapeutics, Vivet Therapeutics, HELIXMITH Co, Rocket Pharmaceuticals, Bristol-Myers Squibb, Wellington Zhaotai Therapies, Reyon Pharmaceutical, Neowise Biotechnology, Orna Therapeutics, Genflow Biosciences, Xylocor Therapeutics, Kolon TissueGene, Allogene Therapeutics, Nanjing IASO Biotherapeutics, Shanghai Vitalgen BioPharma, Rui Therapeutics, Obsidian Therapeutics, YolTech Therapeutics, Neurotech USA, Beacon Therapeutics, REGENXBIO and others. Promising Gene Therapy Therapies such as Tipifarnib, Sucrose (3%), Chemotherapy, UX111, SPK-8011, SBT101, Abemaciclib, PI3K Inhibitor paxalisib, Entrectinib and others. Discover groundbreaking developments in Gene Therapy Therapies! Gain in-depth knowledge of key clinical trials, emerging drugs, and market opportunities @ Gene Therapy Clinical Trials Assessment Gene Therapy Marketed Therapies Novartis Novartis is reimagining medicine to improve and extend people's lives. As a leading global medicines company, company use innovative science and digital technologies to create transformative treatments in areas of great medical need. In quest to find new medicines, consistently rank among the world's top companies investing in research and development. Novartis products reach more than 750 million people globally and are finding innovative ways to expand access to company latest treatments. Novartis Gene Therapies is reimagining medicine to transform the lives of people living with rare genetic diseases. Utilizing cutting-edge technology, company is working to turn promising gene therapies into proven treatments. Zolgensma Zolgensma (onasemnogene abeparvovec) is the only gene therapy for spinal muscular atrophy (SMA) and the only SMA treatment designed to directly address the genetic root cause of the disease by replacing the function of the missing or non-working SMN gene to halt disease progression through sustained SMN protein expression with a single, one-time IV infusion. Zolgensma was approved by the US Food and Drug Administration for the treatment of pediatric patients less than 2years of age with spinal muscular atrophy (SMA) with bi-allelic mutations in the survival motor neuron 1 (SMN1) gene. . Zolgensma is now approved in more than 40 countries and more than 2,000 patients have been treated with Zolgensma globally across clinical trials, managed access programs, and in the commercial setting. Spark Therapeutics Spark Therapeutics, is a fully integrated company committed to discovering, developing and delivering gene therapies, challenge the inevitability of genetic diseases, including blindness, hemophilia and neurodegenerative diseases. The company have successfully applied our technology in the first FDA-approved gene therapy in the U.S. for a genetic disease, and currently have three programs in clinical trials, including product candidates that have shown promising early results in patients with hemophilia. At Spark, there is the path to a world where no life is limited by genetic disease. LUXTURNA LUXTURNA is the first FDA-approved gene therapy for a genetic disease, the first and only pharmacologic treatment for an inherited retinal disease (IRD) and the first adeno-associated virus (AAV) vector gene therapy approved in the U.S. LUXTURNA was approved by FDA under Priority Review and previously received orphan drug and breakthrough therapy designations from FDA. With the approval of LUXTURNA, FDA will issue to Spark Therapeutics a Rare Pediatric Disease Priority Review Voucher for a Priority Review of a subsequent marketing application for a different product. Spark Therapeutics' Marketing Authorization Application (MAA) for LUXTURNA is currently under review with the European Medicines Agency (EMA). LUXTURNA also has received orphan product designations from EMA. Gene Therapy Pipeline Therapies Pfizer Pfizer Inc. is a global biopharmaceutical company with a rich history dating back to 1849 when it was founded by Charles Pfizer and Charles Erhart in Brooklyn, New York. The company is engaged in the discovery, development, manufacture, and sale of medicines and vaccines across various therapeutic areas such as vaccines, oncology, internal medicine, hospital, inflammation and immunology, and rare diseases. Pfizer's dedication to global health is evident through its extensive portfolio of medicines and vaccines that aim to enhance wellness, prevention, treatments, and cures for various diseases. The company collaborates with healthcare providers, governments, and communities worldwide to expand access to reliable and affordable healthcare services. Fordadistrogene movaparvovec Fordadistrogene movaparvovec is an investigational recombinant adeno-associated virus serotype 9 (AAV9) capsid carrying a shortened version of the human dystrophin gene (mini-dystrophin) under the control of a human muscle-specific promotor. The AAV9 capsid was chosen as the delivery mechanism because of its potential to target muscle tissue. The FDA has lifted a clinical hold on Pfizer's phase III clinical trial of its investigational gene therapy, fordadistrogene movaparvovec, in patients with Duchenne muscular dystrophy (DMD). Regulatory and ethics approvals to resume the CIFFREO Phase III ambulatory study, including the FDA's lift of its clinical hold, follow reviews of data and protocol amendments. Currently the drug is in Phase III stage of development for the treatment of Duchenne muscular dystrophy Ultragenyx Pharmaceutical Inc Kyowa Kirin strives to create and deliver novel medicines with life-changing value. As a Japan-based Global Specialty Pharmaceutical Company with a more than 70-year heritage, the company apply cutting-edge science including expertise in antibody research and engineering, to address the needs of patients and society across multiple therapeutic areas including Nephrology, Oncology, Immunology/Allergy and Neurology. Across our four regions – Japan, Asia Pacific, North America and EMEA/International – The company focus on purpose, to make people smile, and are united by our shared values of commitment to life, teamwork/Wa, innovation, and integrity. DTX401 DTX401 is an investigational AAV8 gene therapy designed to deliver stable expression and activity of G6Pase-α using a single intravenous infusion. Long term Phase I/II data demonstrate an acceptable safety profile and durability of response. All treated patients have experienced stable or improved glucose control while tapering or discontinuing oral glucose replacement therapy with cornstarch after receiving DTX401. The Phase III GlucoGene study is underway to evaluate the ability of DTX401 to reduce the use of cornstarch while maintaining or improving glucose control as well as the therapy's impact on patients' quality of life. DTX401 was granted Orphan Drug Designation in the United States, EU and United Kingdom, and Regenerative Medicine Advanced Therapy (RMAT) designation and Fast Track designation in the United States. DTX401 was accepted into the EMA's Priority Medicines program (PRIME), enabling more frequent interactions with the EMA and the potential for an accelerated drug has recently completed Phase III clinical trial for the treatment of patients with Glycogen storage disease type I. Rocket Pharmaceuticals Rocket Pharmaceuticals, Inc. is an emerging, clinical-stage biotechnology company focused on developing first-in-class gene therapy treatment options for rare, devastating diseases. Rocket's multi-platform development approach applies the well-established lentiviral vector (LVV) and adeno-associated viral vector (AAV) gene therapy platforms. Rocket's lead clinical program is a LVV-based gene therapy for the treatment of Fanconi Anemia (FA), a difficult to treat genetic disease that leads to bone marrow failure and potentially cancer. Preclinical studies of additional bone marrow-derived disorders are ongoing and target Pyruvate Kinase Deficiency (PKD), Leukocyte Adhesion Deficiency-I (LAD-I) and Infantile Malignant Osteopetrosis (IMO). Rocket's first AAV-based gene therapy program targets Danon disease, a rare neuromuscular and cardiovascular disease. RP-L102 RP-L102 is a gene therapy product containing autologous (patient-derived) hematopoietic stem cells (HSCs) that have been genetically modified with a lentiviral vector to contain a functional copy of the FANCA gene. If given early in life, RP-L102 gene therapy has the potential to serve as a preventative measure, correcting bone marrow cells before there is progression to severe bone marrow failure. RP-L102 has been granted Orphan Drug, Fast Track, and Regenerative Medicine Advanced Therapy (RMAT) designations for the treatment of Fanconi Anemia type A in the United States and Orphan Drug designation in Europe. The drug is currently in Phase II stage of development for the treatment of patients with Fanconi Anemia (FA). Adverum Biotechnologies Adverum Biotechnologies is a clinical-stage gene therapy company targeting unmet medical needs in serious ocular and rare diseases. Adverum is evaluating its novel gene therapy candidate, ADVM-022, as a one-time, intravitreal injection for the treatment of patients with neovascular or wet age-related macular degeneration. ADVM-022 ADVM022 is being developed for the treatment of wet AMD. ADVM-022 utilizes a propriety vector capsid, AAV.7m8, carrying an aflibercept coding sequence under the control of a proprietary expression cassette. Unlike other ophthalmic gene therapies that require a surgery to administer the gene therapy under the retina (sub-retinal approach) ADVM-022 has the advantage of being administered as a one-time IVT injection in the office and is designed to deliver long-term efficacy and reduce the burden of frequent anti-VEGF injections, optimize patient compliance, and improve vision outcomes for patients with wet AMD. The OPTIC trial is designed as a multi-center, open-label, dose-ranging, safety and efficacy trial of ADVM-022 in patients with wet AMD who have demonstrated responsiveness to anti-VEGF treatment. Patients in OPTIC are treatment experienced, and previously required frequent anti-VEGF injections to manage their wet AMD and to maintain functional vision. The drug is currently in Phase II stage of development for the treatment of patients with Wet AMD. Kyverna Therapeutics Kyverna is a patient-centered, clinical-stage biopharmaceutical company focused on developing cell therapies for patients suffering from autoimmune diseases. KYV-101 is advancing through clinical development across two broad areas of autoimmune disease: rheumatology and neurology, including two ongoing multi-center, open-label Phase I trials of KYV-101 in the United States and Germany for patients with lupus nephritis. Kyverna's pipeline includes next-generation chimeric antigen receptor (CAR) T-cell therapies in both autologous and allogeneic formats with properties intended to be well suited for use in B cell-driven autoimmune diseases. By advancing more than one mechanism for taming autoimmunity, Kyverna is positioned to act on its mission of transforming how autoimmune diseases are treated. KYV-101 KYV-101 is an autologous, fully human CD19 CAR T-cell product candidate for use in B cell-driven autoimmune diseases. The CAR in KYV-101 was designed by the National Institutes of Health (NIH) to improve tolerability and tested in a 20-patient Phase I trial in oncology. Results were published by the NIH in Nature Medicine. Kyverna is currently conducting trials of KYV-101 in patients with lupus nephritis, an autoimmune disease in which more than half of patients do not achieve a complete response to current therapies and are at risk of developing kidney failure. Additional clinical trials of KYV-101 in systemic sclerosis, and myasthenia gravis are in preparation. The drug is currently in Phase I/II stage of development for the treatment of patients with Lupus nephritis. Vivet Therapeutics Vivet Therapeutics is a private, clinical-stage biotech company developing novel and long-lasting gene therapies for rare inherited metabolic conditions, including Wilson's disease. Vivet's gene therapy platform uses recombinant adeno-associated viruses (rAAVs) as vectors and has initiated two clinical programs and four pre-clinical assets to date. Its most advanced therapy is VTX-801, a novel gene therapy for Wilson's disease, with key clinical read-outs expected by the end of 2024. Vivet Therapeutics was founded in 2016 by CEO Dr Jean-Philippe Combal and CSO Dr Gloria Gonzalez-Aseguinolaza and is led by a highly experienced management team with deep expertise developing gene therapies and orphan drugs. VTX-802 VTX-802 is an AAV-based gene therapy for patients with Progressive Familial Intrahepatic Cholestasis Type 2. It delivers a codon-optimized version of the BSEP gene to the liver and is currently under preclinical testing. The drug is currently in Preclinical stage of development for the treatment of patients with Intrahepatic cholestasis. Gene Therapy Analytical Perspective by DelveInsight In-depth Commercial Assessment: Gene Therapy Collaboration Analysis by Companies The Report provides in-depth commercial assessment of drugs that have been included, which comprises collaboration, agreement, licensing and acquisition – deals values trends. The sub-segmentation is described in the report which provide company-company collaboration (licensing/partnering), company academic collaboration and acquisition analysis in tabulated form. Gene Therapy Competitive Landscape The report comprises of comparative assessment of Companies (by therapy, development stage, and technology). Gene Therapy Report Assessment Company Analysis Therapeutic Assessment Pipeline Assessment Inactive drugs assessment Unmet Needs Transform your understanding of the Gene Therapy Pipeline! See the latest progress in drug development and clinical research @ Gene Therapy Market Drivers and Barriers, and Future Perspectives Scope of the Gene Therapy Competitive Landscape Report Coverage- Global Gene Therapy Companies- Pfizer, Ultragenyx Pharmaceutical Inc, Rocket Pharmaceuticals, Adverum Biotechnologies, Kyverna Therapeutics, Vivet Therapeutics, HELIXMITH Co, Rocket Pharmaceuticals, Bristol-Myers Squibb, Wellington Zhaotai Therapies, Reyon Pharmaceutical, Neowise Biotechnology, Orna Therapeutics, Genflow Biosciences, Xylocor Therapeutics, Kolon TissueGene, Allogene Therapeutics, Nanjing IASO Biotherapeutics, Shanghai Vitalgen BioPharma, Rui Therapeutics, Obsidian Therapeutics, YolTech Therapeutics, Neurotech USA, Beacon Therapeutics, REGENXBIO and others. Gene Therapy Analytical Perspective: In-depth Commercial Assessment Gene Therapy Unmet Needs, Preclinical and Discovery Stage Products Stay Ahead in Oncology Research–Access the Full Gene Therapy Pipeline Analysis Today! @ Gene Therapy Drugs and Companies Table of Contents Introduction Executive Summary Gene Therapy: Overview Gene Therapy -Analytical Perspective: In-depth Commercial Assessment Competitive Landscape Therapeutic Assessment Gene Therapy: Company and Product Profiles (Marketed Therapies) Novartis Zolgensma Gene Therapy: Company and Product Profiles (Pipeline Therapies) Late Stage Products (Phase III) Pfizer Fordadistrogene movaparvovec Mid Stage Products (Phase II) Rocket Pharmaceuticals RP-L102 Early Stage Products (Phase I/II) Kyverna Therapeutics KYV-101 Preclinical and Discovery Stage Products Vivet Therapeutics VTX-802 Inactive Products Gene Therapy- Unmet needs Gene Therapy – Market drivers and barriers Appendix About Us DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve. Media Contact Company Name: DelveInsight Business Research LLP Contact Person: Yash Bhardwaj Email: Send Email Phone: 09650213330 Address: 304 S. Jones Blvd #2432 City: Las Vegas State: NV Country: United States Website:
Globe and Mail
2 hours ago
- Globe and Mail
Chronic Myeloid Leukemia Pipeline Outlook 2025: Clinical Trial Studies, EMA, PDMA, FDA Approvals, MOA, ROA, NDA, IND, and Companies
DelveInsight's, 'Chronic Myeloid Leukaemia Pipeline Insight, 2025' report provides comprehensive insights about 20+ companies and 20+ pipeline drugs in Chronic Myeloid Leukaemia pipeline landscape. It covers the Chronic Myeloid Leukemia pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Chronic Myeloid Leukemia pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Explore the comprehensive insights by DelveInsight and stay ahead in understanding the Chronic Myeloid Leukemia Treatment Landscape @ Chronic Myeloid Leukemia Pipeline Outlook Key Takeaways from the Chronic Myeloid Leukemia Pipeline Report On 15 August 2025, M.D. Anderson Cancer Center conducted a phase II trial studies the effect of ASTX727 and dasatinib in treating patients with newly diagnosed Philadelphia chromosome or BCR-ABL positive chronic myeloid leukemia in chronic phase. Philadelphia chromosome positive and BCR-ABL positive are types of genetic mutations (changes). Chemotherapy drugs, such as ASTX727, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Dasatinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. ASTX727 and dasatinib may help to control Philadelphia chromosome-positive chronic myeloid leukemia or BCR-ABL positive chronic myeloid leukemia in chronic phase. On 13 August 2025, Novartis Pharmaceuticals announced a study is to optimize the treatment of asciminib in patients with chronic myelogenous leukemia in chronic phase (CML-CP) previously treated with 2 or more Tyrosine Kinase Inhibitors (TKIs). DelveInsight's Chronic Myeloid Leukemia pipeline report depicts a robust space with 20+ active players working to develop 20+ pipeline therapies for Chronic Myeloid Leukemia treatment. The leading Chronic Myeloid Leukemia Companies such as Kartos Therapeutics, AOP Orphan Pharmaceuticals, Biokine Therapeutics, Incyte Corporation, Sana Biotechnology, Novartis, Nerviano Medical Sciences, Sun Pharma Advanced Research Company and others. Promising Chronic Myeloid Leukemia Pipeline Therapies such as Imatinib mesyl, Dasatinib, Nilotinib, decitabine (5-aza-2'deoxycytidine), Asciminib, Bosutinib, Peginterferon alfa-2a, and others. Discover groundbreaking developments in Chronic Myeloid Leukemia Therapies! Gain in-depth knowledge of key clinical trials, emerging drugs, and market opportunities @ Chronic Myeloid Leukemia Ongoing Clinical Trials Assessment Chronic Myeloid Leukemia Emerging Drugs Profile Navtemadlin : Kartos Therapeutics Navtemadlin (KRT-232) is a novel, potent, and selective oral MDM2 inhibitor. Currently, the drug is undergoing an Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of KRT-232 Combined with a Tyrosine Kinase Inhibitor (TKI) in Patients with Relapsed or Refractory Ph+ Chronic Myeloid Leukemia (CML). Ropeginterferon alfa 2b : AOP Orphan Pharmaceuticals Ropeginterferon alfa-2b was discovered by PharmaEssentia Corp. based in Taiwan. BESREMi (Ropeginterferon alfa-2b) is a novel, long-acting, mono-pegylated proline interferon .Its pharmacokinetic properties offer a new level of tolerability. The Chronic Myeloid Leukemia Pipeline Report Provides Insights into The report provides detailed insights about companies that are developing therapies for the treatment of Chronic Myeloid Leukemia with aggregate therapies developed by each company for the same. It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Chronic Myeloid Leukemia Treatment. Chronic Myeloid Leukemia Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects. Chronic Myeloid Leukemia Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Chronic Myeloid Leukemia market Stay informed about the Chronic Myeloid Leukemia pipeline trends! Uncover critical updates on therapeutic innovations and their potential impact on patients and the healthcare industry @ Chronic Myeloid Leukemia Unmet Needs Chronic Myeloid Leukemia Companies Kartos Therapeutics, AOP Orphan Pharmaceuticals, Biokine Therapeutics, Incyte Corporation, Sana Biotechnology, Novartis, Nerviano Medical Sciences, Sun Pharma Advanced Research Company and others. Chronic Myeloid Leukaemia pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as Intra-articular Intraocular Intrathecal Intravenous Ophthalmic Oral Parenteral Subcutaneous Topical Transdermal Molecule Type Chronic Myeloid Leukemia Products have been categorized under various Molecule types such as Oligonucleotide Peptide Small molecule Product Type Transform your understanding of the Chronic Myeloid Leukemia Pipeline! See the latest progress in drug development and clinical research @ Chronic Myeloid Leukemia Market Drivers and Barriers, and Future Perspectives Scope of the Chronic Myeloid Leukemia Pipeline Report Coverage- Global Chronic Myeloid Leukemia Companies- Kartos Therapeutics, AOP Orphan Pharmaceuticals, Biokine Therapeutics, Incyte Corporation, Sana Biotechnology, Novartis, Nerviano Medical Sciences, Sun Pharma Advanced Research Company and others. Chronic Myeloid Leukemia Pipeline Therapies- Imatinib mesyl, Dasatinib, Nilotinib, decitabine (5-aza-2'deoxycytidine), Asciminib, Bosutinib, Peginterferon alfa-2a, and others. Chronic Myeloid Leukemia Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination Chronic Myeloid Leukemia Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III Stay Ahead in Oncology Research–Access the Full Chronic Myeloid Leukemia Pipeline Analysis Today! @ Chronic Myeloid Leukemia Drugs and Companies Table of Contents Introduction Executive Summary Chronic Myeloid Leukaemia: Overview Pipeline Therapeutics Therapeutic Assessment Chronic Myeloid Leukaemia– DelveInsight's Analytical Perspective Late Stage Products (Phase III) Drug Name : Company Name Mid Stage Products (Phase I/ II) Navtemadlin: Kartos Therapeutics Early Stage Products (Phase I) Drug Name: Company Name Preclinical and Discovery Stage Products Drug Name: Company Name Inactive Products Chronic Myeloid Leukaemia Key Companies Chronic Myeloid Leukaemia Key Products Chronic Myeloid Leukaemia- Unmet Needs Chronic Myeloid Leukaemia- Market Drivers and Barriers Chronic Myeloid Leukaemia- Future Perspectives and Conclusion Chronic Myeloid Leukaemia Analyst Views Chronic Myeloid Leukaemia Key Companies About Us DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve. Media Contact Company Name: DelveInsight Business Research LLP Contact Person: Yash Bhardwaj Email: Send Email Phone: 09650213330 Address: 304 S. Jones Blvd #2432 City: Las Vegas State: NV Country: United States Website:
